Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.36 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27789311 | 0.89 | NR3C2 (0.46) | NR3C2PTPN7DUSP3ARKIF11 | |
| SCHEMBL78974 | 0.86 | DAO (0.49) | GPR84KIF11DAOP2RX7PDPK1 | |
| SCHEMBL297428 | 0.84 | NR3C2 (0.48) | NR3C2PTPN7DUSP3ARGPR84 | |
| SCHEMBL81056 | 0.82 | NR3C2 (0.47) | NR3C2PTPN7DUSP3ARGPR84 | |
| SCHEMBL29766263 | 0.81 | PTPN7 (0.48) | NR3C2PTPN7DUSP3ARKIF11 | |
| SCHEMBL118433 | 0.81 | PTPN7 (0.48) | NR3C2PTPN7DUSP3ARKIF11 | |
| SCHEMBL11707484 | 0.81 | GPR84 (0.55) | GPR84DAOSLC6A4 | |
| SCHEMBL3244152 | 0.79 | TAAR1 (0.53) | NR3C2PTPN7DUSP3ARCYP2D6 | |
| SCHEMBL19309519 | 0.79 | HTR2A (0.49) | NR3C2CYP3A4SLC6A4 | |
| SCHEMBL80232 | 0.79 | DAO (0.42) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | NR3C2 128/4885PTPN7 161/4885DUSP3 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.